BRIEF-Protalix Biotherapeutics announces positive interim results from phase II clinical trial of Alidornase Alfa
January 03, 2017 at 07:53 AM EST
* Protalix Biotherapeutics announces positive interim results from phase ii clinical trial of Alidornase Alfa (air dnase) for the treatment of cystic fibrosis